Brought to you by 
Ligand acquires Vernalis for $42.3mm
27 Apr 2021
Executive Summary
Ligand Pharmaceuticals Inc. launched an offer to acquire publicly traded biotech Vernalis PLC (structure-based drug discovery). The offer, which requires approval by at least 75% of Vernalis stockholders, has received support of 67% so far, including its two largest shareholders (IAML and Woodford Investment Management). Earlier this year, Vernalis announced it was looking for strategic alternatives to cope with closure of its US commercial operations.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ligand acquires Vernalis for $42.3mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice